Back to top
more

ADC Therapeutics (ADCT)

(Delayed Data from NYSE)

$2.64 USD

2.64
420,553

0.00 (0.00%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

Zacks Equity Research

Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)

by Zacks Equity Research

The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround

by Zacks Equity Research

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Zacks Equity Research

Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.

Zacks Equity Research

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.

Zacks Equity Research

Earnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ADC Therapeutics SA (ADCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Centene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?

by Zacks Equity Research

Centene's (CNC) second-quarter results are likely to reflect growth in premiums.

Zacks Equity Research

Teladoc Health (TDOC) Gears Up for Q2 Earnings: What Lies Ahead?

by Zacks Equity Research

Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy ADC Therapeutics (ADCT) Ahead of Earnings?

by Zacks Equity Research

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

by Zacks Equity Research

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why ADC Therapeutics (ADCT) Might Surprise This Earnings Season

by Zacks Equity Research

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Upgraded to Buy: Here's Why

by Zacks Equity Research

ADC Therapeutics SA (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is a Surprise Coming for ADC Therapeutics (ADCT) This Earnings Season?

by Zacks Equity Research

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?

by Zacks Equity Research

Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.

Zacks Equity Research

Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.

Zacks Equity Research

bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.